Acazicolcept  (Synonyms: ALPN-101)

Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities^[1].

Human

Acazicolcept (267-400 μg/mouse; i.p.; twice a week; for 6 weeks) decreases dermal and pulmonary fibrosis and alleviates pulmonary hypertension^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2797026-97-0

Liquid

Colorless to light yellow

[Acazicolcept]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [ICOSLG (inducible T-cell co-stimulator ligand, B7H2, B7-H2, ICOS-L, B7-related protein 1, B7RP1, B7RP-1, B7 homolog 2, B7 homologue 2, GL50, KIAA0653, CD275)N-terminal fragment (1-122)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized Acazicolcept can bind Human ICOS Protein (His Tag). The EC₅₀ for this effect is 0.43 ng/mL.

• [1]. Cindy Orvain, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Res Ther. 2022 Jan 5;24(1):13.  [Content Brief]